SynthesisBMC infectious diseases2025
Human papilloma virus genotypes associated with non-cervical HPV positive cancer development in UK and Ireland cohorts: a systematic review.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Human papilloma virus genotypes associated with non-cervical HPV positive cancer development in UK and Ireland cohorts: a systematic review.BMC infectious diseases · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman Papillomavirus (HPV) is an infectious agent notably associated with viral carcinogenesis of the cervix. Since 2019, the UK and Ireland have used the Gardasil-9 HPV vaccine to prevent new cases of HPV-positive cancers. This systematic review aims to assess whether the current HPV vaccination programme provides substantive protection against developing non-cervical HPV-positive cancers.
methodsRelevant studies were identified using the OVID-Medline and EMBASE databases. Screening and data extraction were conducted using the systematic review software Covidence. Risk of bias was assessed using the Hoy et al. tool, and statistical analysis was conducted using R statistical software (v 4.3.1).
resultsBased on pre-defined search parameters, 4,086 papers were identified for screening. Following the title, abstract, and full-text review, data was extracted from 30 eligible studies. A total of 1,389 patients with HPV-positive cancers, with 24 unique HPV genotypes, were considered for analysis in this review. The most prevalent genotype across all patients was HPV16 (95.9%, 1,332/1,389). Genotypic diversity was notably greater in penile cancers compared to other non-cervical HPV-related cancers considered in the present study, with 21 HPV genotypes reported in this site alone compared to two in vaginal and vulvar cancers (p = 1.8E-3). Gardasil-9 was found to offer protection against 37.5% (9/24) of the unique HPV genotypes identified. However, if this vaccine had been available, there would have been sufficient genotype-specific protection to prevent 9 out of 10 HPV-positive cancers (97.8%, 1,359/1,389) retrospectively identified in the current study. It should be noted that significant regional differences in the heterogeneity of reported HPV genotypes (p < 1.0E-05) were illustrated, with London-based cohorts having the most HPV-positive cancers associated with unprotected HPV genotypes (4.7%, 31/658).
conclusionThis systematic review confirms HPV16 as the dominant genotype in HPV-positive cancers and highlights the genotypic diversity in non-cervical HPV-positive cancers. Moreover, while HPV vaccination using Gardasil-9 provides limited genotype-specific protection, it could have prevented nearly all HPV-positive cancers reported in eligible studies. Regional differences were minimal, but London had the highest proportion of unprotected genotypes. This suggests that while vaccination is highly effective in preventing HPV-related cancers, gaps in protection remain, particularly for less common genotypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.